UNASSIGNED:为了从西班牙单中心的角度评估使用下一代测序(NGS)与序贯单一检测(SST)进行分子诊断和治疗晚期非小细胞肺癌(NSCLC)患者的成本效益,VirgendelRocio大学医院(HUVR)。
UNASSIGNED:开发了一个决策树模型来评估晚期NSCLC患者的改变检测改变和诊断成本。比较NGS与SST。模型输入,如测试,阳性率,或治疗分配均通过文献和HUVR专家的临床实践咨询获得。进行了一些敏感性分析来测试模型的稳健性。
未经证实:使用NGS对100名患者的假设队列进行分子诊断,与使用SST相比,可以检测到更多的改变,并且可以在临床试验中招募更多的患者。另一方面,使用NGS而不是SST的诊断成本增加到20,072欧元。使用NGS的结果时间将从16.7天减少到9天。
UNASSIGNED:与SST相比,在检测到的改变方面,在HUVR中实施NGS以诊断晚期NSCLC患者提供了显着的临床益处。靶向治疗和临床试验登记,并且可以被认为是一种具有成本效益的策略。
UNASSIGNED: To assess the cost-effectiveness of using next-generation sequencing (NGS) compared to sequential single-testing (SST) for molecular diagnostic and treatment of patients with advanced non-small cell lung cancer (NSCLC) from a Spanish single-center perspective, the Hospital Universitario Virgen del Rocio (HUVR).
UNASSIGNED: A decision-tree model was developed to assess the alterations detection alterations and diagnostic cost in patients with advanced NSCLC, comparing NGS versus SST. Model inputs such as testing, positivity rates, or treatment allocation were obtained from the literature and the clinical practice of HUVR experts through consultation. Several sensitivity analyses were performed to test the robustness of the model.
UNASSIGNED: Using NGS for molecular diagnosis of a 100-patients hypothetical cohort, 30 more alterations could be detected and 3 more patients could be enrolled in clinical-trials than using SST. On the other hand, diagnostic costs were increased up to €20,072 using NGS instead of SST. Using NGS time-to-results would be reduced from 16.7 to 9 days.
UNASSIGNED: The implementation of NGS at HUVR for the diagnostic of patients with advanced NSCLC provides significant clinical benefits compared to SST in terms of alterations detected, treatment with targeted-therapies and clinical-trial enrollment, and could be considered a cost-effective strategy.